Clarithromycin

Safety Summary

Regulatory Status

Sources

These citations are the ones recorded for the human adult context.

• FDA Prescribing Information: Clarithromycin (Biaxin) — macrolide; potent CYP3A4 inhibitor; statin/colchicine contraindications; QT prolongation; H. pylori triple therapy; MAC; neonatal pyloric stenosis; cardiac safety signal; XL formulation (2023) REGULATORY · 2023
• WHO AWaRe Classification of Antibiotics — Access/Watch/Reserve categories; stewardship framework; amoxicillin Access category; ciprofloxacin/azithromycin Watch; vancomycin Reserve; resistance drivers; outpatient prescribing guidance (2023) REGULATORY · 2023
• OEHHA Proposition 65 List of Carcinogens or Reproductive Toxicants (CSV, list date 31-Jul-26) REGULATORY
• Permissible Exposure Limits – OSHA Annotated Table Z-1 REGULATORY
• EPA CompTox CTX API: predicted properties for DTXSID3022829 (Clarithromycin) REFERENCE

Same data as the API response, which is open and needs no key. The full per-record source list is available to authenticated callers.